PRECISION BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Precision BioSciences, Inc. | ||
| Date: March 26, 2025 | By: | /s/ Michael Amoroso |
|---|---|---|
| Michael Amoroso | ||
| President, Chief Executive Officer and Director(principal executive officer and authorized signatory) | ||
| Date: March 26, 2025 | By: | /s/ John Alexander Kelly |
|---|---|---|
| John Alexander Kelly | ||
| Chief Financial Officer(principal financial and accounting officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Michael Amoroso | President, Chief Executive Officer and Director(principal executive officer) | March 26, 2025 |
| Michael Amoroso | ||
| /s/ John Alexander Kelly | Chief Financial Officer(principal financial and accounting officer) | March 26, 2025 |
| John Alexander Kelly | ||
| /s/ Kevin Buehler | Chair of the Board and Director | March 26, 2025 |
| Kevin Buehler | ||
| /s/ Melinda Brown | Director | March 26, 2025 |
| Melinda Brown | ||
| /s/ Stanley Frankel, M.D. | Director | March 26, 2025 |
| Stanley Frankel, M.D. | ||
| /s/ Geno Germano | Director | March 26, 2025 |
| Geno Germano | ||
| /s/ Shari Lisa Piré | Director | March 26, 2025 |
| Shari Lisa Piré | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) | F-1 |
|---|---|
| Balance Sheets as of December 31, 2024 and December 31, 2023 | F-3 |
| Statements of Operations for the Years Ended December 31, 2024 and December 31, 2023 | F-4 |
| Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2024 and December 31, 2023 | F-5 |
| Statements of Cash Flows for the Years Ended December 31, 2024 and December 31, 2023 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.